Seth Chaney is a health technology strategist with a unique blend of expertise in biomedical informatics, digital health infrastructure, and commercial innovation. He began his career at Eli Lilly supporting data platforms and scientific workflows in the drug development labs, then transitioned into digital health, where he worked across diabetes, immunology, and neurology to develop connected therapeutic solutions—including EHR-integrated diabetes management systems that advanced clinical decision-making and patient outcomes.

Seth later evolved into a commercial leader, driving the EHR and health IT go-to-market strategy for Zepbound and Mounjaro, two blockbuster therapies redefining metabolic health. He also played a pivotal role in launching the first-ever pharmacy experience through LillyDirect with the Zepbound vial, while embedding brand strategy directly into EHR workflows and point-of-care systems to deliver measurable ROI. Operating at the intersection of science, technology, and real-world implementation, Seth bridges clinical innovation with digital ecosystems to create lasting commercial and patient impact.